Bergenin suppresses the growth of colorectal cancer cells by inhibiting PI3K/AKT/mTOR signaling pathway
Purpose: To investigate anticancer effects of bergenin on human colorectal cancer cell lines.
Methods: Human colorectal adenocarcinoma cell line HCT116 was treated with various concentrations of bergenin for 24 and 48 h. Cell viability, apoptosis, cell cycle arrest and reactive oxygen species (ROS) level were analyzed by MTT, flow cytometry and fluorescent dye assays, respectively. DNA damage-associated protein expressions were analyzed by Western blotting.
Results: Bergenin significantly suppressed the viability of HCT116 cells. Moreover, bergenin induced cells to accumulate in G1 phase and resulted in DNA breaks in HCT116 cells. It also led to marked accumulation of intracellular reactive oxygen species (ROS), a breaker of DNA strand in HCT116 cells. Interestingly, bergenin inhibited PI3K/AKT/mTOR pathway.
Conclusion: Bergenin effectively suppresses the growth of colorectal adenocarcinoma by inducing generation of intracellular ROS, DNA damage and consequent G1 phase arrest via inhibition of PI3K/AKT/mTOR pathway.
Keywords: Bergenin, Colorectal cancer, DNA damage, Cell cycle arrest, PI3K/AKT/mTOR
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.